Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simris Alg AB's ROE % for the quarter that ended in Mar. 2026 was -986.60%. Simris Alg AB's PB Ratio for the quarter that ended in Mar. 2026 was 24.95.
Simris Alg AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -39.54%.
Simris Alg AB ROE % Adjusted to Book Value Related Terms
Simris Alg AB ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Simris Alg AB's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SIMRIS B vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Simris Alg AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simris Alg AB ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Simris Alg AB's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Simris Alg AB's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -39.54% mean?
Simris Alg AB (OSTO:SIMRIS B) has a ROE % Adjusted to Book Value of -39.54% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Simris Alg AB and its competitors.
Is Simris Alg AB's ROE % Adjusted to Book Value too high?
Simris Alg AB's current ROE % Adjusted to Book Value is -39.54%. Overall, Simris Alg AB has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simris Alg AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
Simris Alg AB's ROE % Adjusted to Book Value of -39.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Simris Alg AB and its competitors. Simris Alg AB's current ROE % Adjusted to Book Value is -39.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simris Alg AB stock overvalued right now?
Based on GuruFocus' analysis, Simris Alg AB (OSTO:SIMRIS B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 273.3% above its estimated fair value. The current ROE % Adjusted to Book Value is -39.54%. Simris Alg AB's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Simris Alg AB (OSTO:SIMRIS B), the current ROE % Adjusted to Book Value is -39.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simris Alg AB (OSTO:SIMRIS B) Overvalued in 2026?
Based on GuruFocus' analysis, Simris Alg AB stock appears to be overvalued.
The current stock price of kr0.11 is trading 273.3% above its estimated GF Value™ of kr0.03.
GuruFocus considers Simris Alg AB to be Significantly Overvalued.
Key valuation signals for OSTO:SIMRIS B:
ROE % Adjusted to Book Value: -39.54%
GF Value™: kr0.03 vs. price of kr0.11 (273.3% above fair value)
No single metric tells the full story. See the OSTO:SIMRIS B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.
19GF Score
Get the complete analysis for OSTO:SIMRIS B
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SIMRIS B has been successfully added to your 
